NCT00531271View on ClinicalTrials.gov

ABI-008 Trial in Patients With Metastatic Breast Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL

Enrollment

85

Participants

Timeline

Start Date

November 1, 2007

Primary Completion Date

December 1, 2008

Study Completion Date

December 1, 2008

Conditions

Metastatic Breast Cancer

Interventions

DRUG

ABI-008 (nab-docetaxel)

ABI-008; 60-200 mg/m²; Intravenous infusion every 3 weeks.

Trial Locations (1)

77030

University of Texas M.D. Anderson Cancer Center, Houston

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Celgene

INDUSTRY